<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5452625</article-id><article-id pub-id-type="publisher-id">1335</article-id><article-id pub-id-type="doi">10.1186/s13075-017-1335-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ez-Zaitouni</surname><given-names>Zineb</given-names></name><address><email>z.ez-zaitouni@lumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hilkens</surname><given-names>Andrea</given-names></name><address><email>andrea_hilkens@hotmail.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gossec</surname><given-names>Laure</given-names></name><address><email>laure.gossec@psl.aphp.fr</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Berg</surname><given-names>Inger Jorid</given-names></name><address><email>Inger.Berg@diakonsyk.no</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Landew&#233;</surname><given-names>Robert</given-names></name><address><email>landewe@rlandewe.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ramonda</surname><given-names>Roberta</given-names></name><address><email>roberta.ramonda@unipd.it</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Dougados</surname><given-names>Maxime</given-names></name><address><email>maxime.dougados@cch.aphp.fr</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>van der Heijde</surname><given-names>D&#233;sir&#233;e</given-names></name><address><email>mail@dvanderheijde.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Gaalen</surname><given-names>Floris</given-names></name><address><email>F.A.van_Gaalen@lumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000089452978</institution-id><institution-id institution-id-type="GRID">grid.10419.3d</institution-id><institution>Department of Rheumatology, </institution><institution>Leiden University Medical Center, </institution></institution-wrap>P.O. Box 9600, 2300 RC Leiden, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution/><institution>Sorbonne Universit&#233;s, </institution></institution-wrap>UPMC Univ Paris 06, GRC-08, Paris, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Rheumatology Department, </institution><institution>Pitie-Salp&#233;tri&#232;re Hospital, AP-HP, </institution></institution-wrap>Paris, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0512 8628</institution-id><institution-id institution-id-type="GRID">grid.413684.c</institution-id><institution>Department of Rheumatology, </institution><institution>Diakonhjemmet Hospital, </institution></institution-wrap>Oslo, Norway </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000000404654431</institution-id><institution-id institution-id-type="GRID">grid.5650.6</institution-id><institution>Department of Clinical Immunology and Rheumatology, </institution><institution>Amsterdam Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 3470</institution-id><institution-id institution-id-type="GRID">grid.5608.b</institution-id><institution>Rheumatology Unit, Department of Medicine DIMED, </institution><institution>University of Padova, </institution></institution-wrap>Padova, Italy </aff><aff id="Aff7"><label>7</label>Paris Descartes University, H&#244;pital Cochin, Assistance Publique-H&#244;pitaux de Paris, INSERM (U1153): Epid&#233;miologie Clinique et Biostatistiques, PRES Sorbonne Paris-Cit&#233;, Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>19</volume><elocation-id>118</elocation-id><history><date date-type="received"><day>17</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#169; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The Assessment of SpondyloArthritis international Society (ASAS) definition of a positive family history (PFH) of spondyloarthritis (SpA) includes the following diseases in first- or second-degree relatives: ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and psoriasis. However, it is not known if a PFH for each of these diseases contributes to making a diagnosis of axSpA, sacroiliitis on imaging, or fulfilling the ASAS criteria in patients presenting with chronic back pain (CBP). Therefore, the aim of this study was to assess which SpA diseases in family members are associated with human leukocyte antigen B27 (HLA-B27) and axial spondyloarthritis (axSpA) in CBP patients.</p></sec><sec><title>Methods</title><p>CBP patients suspected of axSpA from the SPACE (<italic>n</italic>&#8201;=&#8201;438) and the DESIR (<italic>n</italic>&#8201;=&#8201;647) cohort were asked about the presence of SpA diseases in first- or second-degree relatives (AS, AAU, ReA, IBD, and psoriasis). The associations between a PFH and HLA-B27, sacroiliitis on imaging (magnetic resonance imaging (MRI) or radiographs), axSpA diagnosis, and ASAS classification in CBP patients were assessed.</p></sec><sec><title>Results</title><p>In the SPACE and the DESIR cohort, a PFH of AS (odds ratio (OR) 5.9 (95% confidence interval (CI) 3.5&#8211;9.9), and OR 3.3 (95% CI 2.1&#8211;5.2)) and a PFH of AAU (OR 9.8 (95% CI 3.3&#8211;28.9) and OR 21.6 (95% CI 2.9&#8211;160.1)) were significantly associated with presence of HLA-B27. Furthermore, in both cohorts a PFH of AS and a PFH of AAU were positively associated with fulfilment of the ASAS criteria, but not with sacroiliitis on imaging. In SPACE but not in DESIR a PFH of AAU was positively associated with axSpA diagnosis. In both cohorts a PFH of ReA, IBD, or psoriasis was not positively associated with HLA-B27 positivity, sacroiliitis on imaging, axSpA diagnosis, or meeting the ASAS criteria for axSpA.</p></sec><sec><title>Conclusions</title><p>In our cohorts, a PFH of AS or AAU is useful for case-finding of axSpA as this is correlated with HLA-B27 carriership. However, as a PFH of ReA, IBD, or psoriasis does not contribute to identifying axSpA in CBP patients, these data suggest that the widely used ASAS definition of a PFH of SpA should be updated.</p></sec><sec><title>Trial registration</title><p>Trial registration number, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01648907">NCT01648907</ext-link>. Registered on 20 July 2012.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13075-017-1335-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Family history</kwd><kwd>Ankylosing spondylitis</kwd><kwd>Acute anterior uveitis</kwd><kwd>Reactive arthritis</kwd><kwd>IBD</kwd><kwd>Psoriasis</kwd><kwd>Axial spondyloarthritis</kwd><kwd>Diagnostic work-up</kwd><kwd>Chronic back pain</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009947</institution-id><institution>Merck Sharp and Dohme</institution></institution-wrap></funding-source><award-id>not applicable</award-id><principal-award-recipient><name><surname>van Gaalen</surname><given-names>Floris</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly involving the spine and sacroiliac joints. Genetic risk factors play a role in axSpA with human leukocyte antigen B27 (HLA-B27) by far the strongest genetic risk factor for disease [<xref ref-type="bibr" rid="CR1">1</xref>]. A positive family history (PFH) of SpA has been reported in up to 40% of ankylosing spondylitis (AS) patients and the risk to develop AS in HLA-B27-positive first-degree relatives of HLA-B27-positive AS patients has been estimated to be 16-times higher than that of HLA-B27-positive individuals in the general population [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. As a result, familial aggregation of SpA is considered a risk indicator for the presence of axSpA in patients with chronic back pain (CBP) and is part of several SpA classification criteria sets [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>In the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA, a PFH of SpA is defined as the presence of any of the following diseases in first- or second-degree relatives: AS, acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and psoriasis [<xref ref-type="bibr" rid="CR8">8</xref>]. This PFH definition is also recommended in diagnosing axSpA, and is incorporated in several referral strategies for CBP patients used by nonrheumatologists [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p>However, only three of these diseases have a documented HLA-B27 association (i.e., AS, AAU, and ReA) and two are not HLA-B27 associated (i.e., IBD and psoriasis) [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. Thus, even though a PFH of SpA is a common finding in axSpA patients it is unknown whether a PFH of each of these diseases contributes equally well to making a diagnosis of axSpA in patients presenting with CBP.</p><p>In this study, we present data from two unique early axSpA cohorts: the multinational multicenter SPondyloArthritis Caught Early (SPACE) cohort and the French multicenter DEvenir des Spondylarthropathies Indiff&#233;renci&#233;es R&#233;centes (DESIR) cohort. In these cohorts of CBP patients with a suspicion of axSpA we have investigated which of the SpA diseases present among family members were associated with HLA-B27, sacroiliitis on imaging, a clinical diagnosis of axSpA, and meeting the ASAS classification criteria for axSpA.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patient cohorts</title><p>The SPACE cohort is a prospective study which includes patients with short-term CBP (&#8805;3&#160;months, &#8804;2&#160;years, and an onset &lt;45&#160;years) at a minimum age of 16&#160;years from five Rheumatology outpatient clinics in the Netherlands, Norway, and Italy. DESIR is a prospective longitudinal cohort running in 25 centers in France (clinicaltrials.gov, NCT01648907). Patients between the ages of 18 and 50&#160;years with inflammatory back pain (IBP) according to the Calin [<xref ref-type="bibr" rid="CR14">14</xref>] or Berlin [<xref ref-type="bibr" rid="CR15">15</xref>] criteria, persisting &#8805;3&#160;months but &lt;3&#160;years, were included. In addition, the treating rheumatologist had to have a substantial suspicion of axSpA (level of confidence &#8805;5 on a 0&#8211;10 rating scale, where 0&#8201;=&#8201;not confident and 10&#8201;=&#8201;very confident). A detailed description of both cohorts is provided elsewhere [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Both studies were approved by local medical ethics committees. All participants provided prior written informed consent.</p></sec><sec id="Sec4"><title>Clinical data collection</title><p>All patients underwent a diagnostic work-up according to a fixed protocol which includes physical examination, laboratory assessments (HLA-B27, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR)), and magnetic resonance imaging (MRI) as well as radiographs of sacroiliac joints. The presence and history of clinical SpA features were assessed: IBP, good response to nonsteroidal anti-inflammatory drugs (NSAIDs), peripheral arthritis, dactylitis, enthesitis, AAU, IBD, and psoriasis. Patients were asked about the presence of any of the following SpA diseases in first- or second-degree relatives: AS, AAU, ReA, IBD, and psoriasis. For each SpA disease the possible answers were &#8220;yes&#8221;, &#8220;no&#8221; or &#8220;unknown/uncertain&#8221;. A PFH was defined as the presence of &#8805;1 SpA-related disease in first- (mother, father, sister, brother, daughter, son) or second-degree relatives (aunt, uncle, niece, nephew, grandmother, and grandfather) reported by the patient [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>In the SPACE cohort, axSpA was diagnosed by the treating rheumatologist. In the DESIR cohort axSpA diagnosis was defined as the level of confidence regarding diagnosis of &#8805;8 on a 0&#8211;10 numerical rating scale (where 0&#8201;=&#8201;not confident at all and 10&#8201;=&#8201;very confident). The ASAS axSpA classification criteria were used to classify patients.</p></sec><sec id="Sec5"><title>Data analysis</title><p>Baseline demographic and clinical characteristics are presented using descriptive statistics for both the SPACE and DESIR cohorts. The association between each PFH disease and HLA-B27 in patients was assessed using the Chi-squared test. Similar analyses were performed for the assessment of the association between each PFH disease and a clinical diagnosis of axSpA, sacroiliitis on imaging (defined as either sacroiliitis on MRI, radiographs, or on both modalities by local reading), and the fulfilment of the ASAS axSpA classification criteria.</p><p>Statistical testing was performed using Stata SE v.14 (StataCorp LP, College Station, TX, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p>For the current analyses, 438 patients from the SPACE cohort and 647 patients from the DESIR cohort with complete data at baseline were used (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Several baseline characteristics differed between the two cohorts, mainly reflecting differences in inclusion criteria. In both cohorts, the distribution of all PFH diseases (AS, AAU, ReA, IBD, and psoriasis) in first- or second-degree relatives were similar.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics and clinical features of CBP patients in the SPACE (<italic>n</italic>&#8201;=&#8201;438) and DESIR cohorts (<italic>n</italic>&#8201;=&#8201;647)</p></caption><table-wrap-foot><p>Unless specified otherwise, results are presented as mean&#8201;&#177;&#8201;SD or number (%)</p><p>*Inclusion criterion</p><p>
<sup>a</sup>Back pain not present anymore or is much better 24&#8211;48 hours after a full dose of NSAID</p><p>
<sup>b</sup>Values greater than the upper limit of normal</p><p>
<sup>c</sup>Imaging based on local reading. of sacroiliac joints</p><p>
<sup>d</sup>Presence in first- or second-degree relatives of any of the following: AS, AAU, ReA, IBD, or psoriasis</p><p>
<italic>AAU</italic> acute anterior uveitis, <italic>AS</italic> ankylosing spondylitis, <italic>ASAS axSpA</italic> criteria, Assessment of Spondyloarthritis international Society criteria for axial Spondyloarthritis, <italic>CBP</italic> chronic back pain, <italic>CRP</italic> C-reactive protein, <italic>ESR</italic> erythrocyte sedimentation rate, <italic>HLA-B27</italic> human leucocyte antigen B27, <italic>IBD</italic> inflammatory bowel disease, <italic>IBP</italic> inflammatory back pain, <italic>MRI</italic> magnetic resonance imaging, <italic>NSAID</italic> non-steroidal anti-inflammatory drug, <italic>PFH</italic> positive family history, <italic>ReA</italic> reactive arthritis, <italic>SpA</italic> spondyloarthritis</p></table-wrap-foot></table-wrap>
</p><p>In both the SPACE and DESIR cohort, any PFH, a PFH of AS, and a PFH of AAU were significantly associated with HLA-B27 in CBP patients (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). In multivariable analyses, a PFH of AS or AAU were independently associated with HLA-B27 positivity (data not shown). However, in neither cohort was a PFH of ReA, IBD, or psoriasis associated with HLA-B27-positivity.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Association of family history manifestations with HLA-B27 in CBP patients in the SPACE (<italic>n</italic>&#8201;=&#8201;438) and DESIR cohorts (<italic>n</italic>&#8201;=&#8201;647)</p></caption><table-wrap-foot><p>*Two patients with unknown HLA-B27 status</p><p>**One with patient unknown HLA-B27 status</p><p>
<italic>AAU</italic> acute anterior uveitis, <italic>AS</italic> ankylosing spondylitis, <italic>CBP</italic> chronic back pain, <italic>CI</italic> confidence interval, <italic>HLA-B27</italic> human leukocyte antigen B27, <italic>IBD</italic> inflammatory bowel disease, <italic>OR</italic> odds ratio, <italic>PFH</italic> positive family history (manifestation in first- or second-degree relatives), <italic>ReA</italic> reactive arthritis</p></table-wrap-foot></table-wrap>
</p><p>To investigate whether the presence of a PFH for any of the diseases in relatives is associated with sacroiliitis, a clinical diagnosis of axSpA, or a positive ASAS classification, similar analyses were performed. In both cohorts, neither &#8216;any PFH&#8217; nor a separate PFH of a disease were associated with sacroiliitis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). In SPACE but not in DESIR a PFH of AAU was positively associated with axSpA diagnosis (Additional file <xref rid="MOESM2" ref-type="media">2</xref>). While a PFH of AS or AAU had a significant positive association with fulfilment of the ASAS criteria, such an association was not found for a PFH of ReA, IBD, or psoriasis in the SPACE and DESIR cohorts (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p>In addition, the relative contribution of HLA-B27 was investigated among patients who were classified according to the ASAS criteria. A total of 203 (46%) patients from the SPACE cohort and 410 (63%) patients from the DESIR cohort fulfilled the ASAS criteria for axSpA, and 156 (77%) and 347 (85%) patients were HLA-B27 positive, respectively (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). A PFH was reported more frequently in HLA-B27-positive patients than in HLA-B27-negative patients meeting the ASAS classification criteria (SPACE 45% vs 7% and DESIR 35% vs 6%).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Association of family history manifestations with the fulfilment of ASAS axSpA criteria in the SPACE cohort and DESIR cohorts</p></caption><table-wrap-foot><p>Any PFH, any family history manifestation in first- or second-degree relatives; <italic>AS</italic> ankylosing spondylitis, <italic>AAU</italic> acute anterior uveitis, <italic>ReA</italic> reactive arthritis, <italic>IBD</italic> inflammatory bowel disease, <italic>OR</italic> odds ratio, <italic>95% CI</italic> 95% confidence interval</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>PFH of diseases in first- or second-degree relatives of CBP patients meeting the ASAS axSpA criteria, stratified according to HLA-B27 status</p></caption><table-wrap-foot><p>*Two hundred and three patients fulfilled ASAS-criteria, two with unknown HLA-B27 status</p><p>**Four hundred and ten patients fulfilled ASAS-criteria, one with unknown HLA-B27 status</p><p>
<italic>AAU</italic> acute anterior uveitis, <italic>AS</italic> ankylosing spondylitis, <italic>ASAS axSpA</italic> Assessment of Spondyloarthritis international Society criteria for axial spondyloarthritis, <italic>HLA-B27</italic> human leucocyte antigen B27, <italic>IBD</italic> inflammatory bowel disease, <italic>PFH</italic> postitive family history (manifestation in first- or second-degree relatives), <italic>ReA</italic> reactive arthritis</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec7"><title>Discussion</title><p>To our knowledge this is the first study to investigate the usefulness of the separate SpA diseases in a PFH as defined for the ASAS classification criteria. In two independent cohorts of predominantly Caucasoid Europeans, we found that in CBP patients suspected of axSpA a PFH of ReA, IBD, or psoriasis were neither associated with HLA-B27 positivity, nor with sacroiliitis, a diagnosis of axSpA, or fulfilment of the ASAS criteria. In contrast, a PFH of AS or AAU was strongly correlated with HLA-B27 carriership.</p><p>IBD and psoriasis are generally not HLA-B27-associated diseases, but ReA has been reported to be associated with HLA-B27 in a secondary care setting, although in population-based studies the prevalence of HLA-B27 in ReA was comparable to that of the general population [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. A possible explanation for the absence of the association between ReA and HLA-B27 in our study is that the (self)-reported prevalence of ReA in family members of patients in the SPACE and DESIR cohort was low, suggesting underreporting.</p><p>It is important to emphasize that the current study was performed in patients with predominantly axial symptoms. Although only a PFH of AS or AAU have been shown to be independently associated with HLA-B27, this does not mean that a PFH of the other SpA diseases is always irrelevant [<xref ref-type="bibr" rid="CR19">19</xref>]. For example, the presence of psoriasis in relatives could be relevant in a patient with peripheral symptoms suspected of psoriatic arthritis [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>A strength of this study is the use of two large early axSpA cohorts in which all patients were assessed following a similar protocol which allowed for replication of findings. Strikingly similar prevalences of PFH were found in both cohorts which adds to the credibility of the data. The major limitation of this study, however, is that the diagnosis in relatives (the PFH) is solely based on patients&#8217; information which may have led to either under- or overestimation of a PFH. However, this is similar to most clinical settings in which PFH is also mostly based on self-reporting. Moreover, subdividing a PFH into five different diseases meant that a PFH of, for instance, AAU or ReA was uncommon.</p></sec><sec id="Sec8"><title>Conclusions</title><p>In conclusion, in our two cohorts a PFH of ReA, IBD, and psoriasis does not contribute to diagnosing axSpA in CBP patients suspected of axSpA. A PFH of AS or AAU may be useful in case-finding in low prevalence settings, such as general practice, as these are correlated with HLA-B27 carriership. When replicated, preferably in other regions of the world in patients with a different genetic background, it is justified to remove a PFH of ReA, IBD, and psoriasis from the current ASAS definition of a positive PFH relevant for axSpA.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec50"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13075_2017_1335_MOESM1_ESM.docx"><label>Additional file 1: Table S1.</label><caption><p>Association of family history manifestations with any positive imaging (sacroiliitis on MRI or radiographs) in the SPACE cohort and DESIR cohorts. (DOCX 19 KB)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13075_2017_1335_MOESM2_ESM.docx"><label>Additional file 2: Table S2.</label><caption><p>Association of family history manifestations with clinical diagnosis in the SPACE cohort and DESIR cohorts. (DOCX 19 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAU</term><def><p>Acute anterior uveitis</p></def></def-item><def-item><term>AS</term><def><p>Ankylosing spondylitis</p></def></def-item><def-item><term>ASAS</term><def><p>Assessment of SpondyloArthrtis international Society</p></def></def-item><def-item><term>axSpA</term><def><p>Axial spondyloarthritis</p></def></def-item><def-item><term>CBP</term><def><p>Chronic back pain</p></def></def-item><def-item><term>HLA-B27</term><def><p>Human leukocyte antigen B27</p></def></def-item><def-item><term>IBD</term><def><p>Inflammatory bowel disease</p></def></def-item><def-item><term>IBP</term><def><p>Inflammatory back pain</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>PFH</term><def><p>Positive family history</p></def></def-item><def-item><term>ReA</term><def><p>Reactive arthritis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13075-017-1335-8) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The DESIR cohort was sponsored by the D&#233;partement de la Recherche Clinique et du D&#233;veloppement de l&#8217;Assistance Publique&#8211;H&#244;pitaux de Paris. This study is conducted under the umbrella of the French Society of Rheumatology and INSERM (Institut National de la Sant&#233; et de la Recherche M&#233;dicale). The database management is performed within the Department of Epidemiology and Biostatistics (Professor Paul Landais, D.I.M., N&#238;mes, France). An unrestricted grant from Pfizer was allocated for the 10&#160;years of the follow-up of the recruited patients. The authors thank the different regional participating centers: Pr. M. Dougados (Paris, Cochin B), Pr. A. Kahan (Paris, Cochin A), Pr. O. Meyer, Pr. P. Dieud&#233; (Paris, Bichat), Pr. P. Bourgeois, Pr. L. Gossec (Paris, La Piti&#233; Salpetri&#232;re), Pr. F. Berenbaum (Paris, Saint Antoine), Pr. P. Claudepierre (Cr&#233;teil), Pr. M. Breban (Boulogne Billancourt), Dr. B. Saint-Marcoux (Aulnay-sous-Bois), Pr. P. Goupille (Tours), Pr. J-F. Maillefert (Dijon), Dr. X. Pu&#233;chal, Dr. E. Dernis (Le Mans), Pr. D. Wendling (Besan&#231;on), Pr. B. Combe (Montpellier), Pr. L. Euller-Ziegler (Nice), Pr. P. Orcel, Dr. P. Richette (Paris, Lariboisi&#232;re), Pr. P. Lafforgue (Marseille), Dr. P. Boumier (Amiens), Pr. M. Soubrier (Clermont-Ferrand), Dr. N. Mehsen (Bordeaux), Pr. D. Loeuille (Nancy), Pr. R-M. Flipo (Lille), Pr. A. Saraux (Brest), Dr. S. Pavy (Le Kremlin Bic&#234;tre), Pr. A. Cantagrel (Toulouse), Pr. O. Vittecoq (Rouen). The authors also thank URC-CIC Paris Centre for the coordination and monitoring of the study.</p><sec id="FPar1"><title>Funding</title><p>This work was supported by an unrestricted grant from MSD. MSD was not involved in the design of the study, acquisition, analysis, or interpretation of the data, or drafting the manuscript.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets used and/or analyxed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#8217; contributions</title><p>ZE-Z, DvdH, and FvG were responsible for study conception and design. ZE-Z, AH, LG, IJB, RL, RR, MD, and FvG were responsible for acquisition of the data. ZE-Z, AH, DvdH, and FvG participated in interpretation and analysis of the data. ZE-Z drafted and wrote the manuscript. ZE-Z, AH, LG, IJB, RL, RR, MD, DvdH, and FvG were involved in critically revising the manuscript for important intellectual content. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Authors&#8217; information</title><p>All authors read and approved this manuscript.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar7"><title>Ethics approval and consent to participate</title><p>The SPACE cohort has been approved by the medical ethical committee of the Leiden University Medical Center (reference number: P08.105). DESIR has been approved by the &#206;le de France III Ethics Committee (reference number: 2457). All necessary consent approval was obtained from any patient involved in the study.</p></sec><sec id="FPar8"><title>Publisher&#8217;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlosstein</surname><given-names>L</given-names></name><name><surname>Terasaki</surname><given-names>PI</given-names></name><name><surname>Bluestone</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>CM</given-names></name></person-group><article-title>High association of an HL-A antigen, W27, with ankylosing spondylitis</article-title><source>N Engl J Med</source><year>1973</year><volume>288</volume><issue>14</issue><fpage>704</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1056/NEJM197304052881403</pub-id><?supplied-pmid 4688372?><pub-id pub-id-type="pmid">4688372</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedendo</surname><given-names>A</given-names></name><name><surname>Glorioso</surname><given-names>S</given-names></name><name><surname>Pasini</surname><given-names>CV</given-names></name><name><surname>Fabiano</surname><given-names>F</given-names></name><name><surname>Casara</surname><given-names>D</given-names></name><name><surname>Cavallo</surname><given-names>A</given-names></name><name><surname>Todesco</surname><given-names>S</given-names></name></person-group><article-title>A family study of ankylosing spondylitis</article-title><source>Rheumatol Int</source><year>1984</year><volume>5</volume><issue>1</issue><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/BF00541362</pub-id><?supplied-pmid 6335595?><pub-id pub-id-type="pmid">6335595</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linden</surname><given-names>SM</given-names></name><name><surname>Valkenburg</surname><given-names>HA</given-names></name><name><surname>de Jongh</surname><given-names>BM</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name></person-group><article-title>The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population</article-title><source>Arthritis Rheum</source><year>1984</year><volume>27</volume><issue>3</issue><fpage>241</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/art.1780270301</pub-id><?supplied-pmid 6608352?><pub-id pub-id-type="pmid">6608352</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Said-Nahal</surname><given-names>R</given-names></name><name><surname>Miceli-Richard</surname><given-names>C</given-names></name><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Duche</surname><given-names>A</given-names></name><name><surname>Dernis-Labous</surname><given-names>E</given-names></name><name><surname>Le Blevec</surname><given-names>G</given-names></name><name><surname>Saraux</surname><given-names>A</given-names></name><name><surname>Perdriger</surname><given-names>A</given-names></name><name><surname>Guis</surname><given-names>S</given-names></name><name><surname>Claudepierre</surname><given-names>P</given-names></name><etal/></person-group><article-title>The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Francais d&#8217;Etude Genetique des Spondylarthropathies</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><issue>6</issue><fpage>1356</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200006)43:6&lt;1356::AID-ANR20&gt;3.0.CO;2-Y</pub-id><?supplied-pmid 10857795?><pub-id pub-id-type="pmid">10857795</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Kennedy</surname><given-names>LG</given-names></name><name><surname>MacGregor</surname><given-names>AJ</given-names></name><name><surname>Darke</surname><given-names>C</given-names></name><name><surname>Duncan</surname><given-names>E</given-names></name><name><surname>Shatford</surname><given-names>JL</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name></person-group><article-title>Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><issue>10</issue><fpage>1823</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/art.1780401015</pub-id><?supplied-pmid 9336417?><pub-id pub-id-type="pmid">9336417</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amor</surname><given-names>B</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Mijiyawa</surname><given-names>M</given-names></name></person-group><article-title>Criteria of the classification of spondylarthropathies</article-title><source>Rev Rhum Mal Osteoartic</source><year>1990</year><volume>57</volume><issue>2</issue><fpage>85</fpage><lpage>9</lpage><?supplied-pmid 2181618?><pub-id pub-id-type="pmid">2181618</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>van der Linden</surname><given-names>S</given-names></name><name><surname>Juhlin</surname><given-names>R</given-names></name><name><surname>Huitfeldt</surname><given-names>B</given-names></name><name><surname>Amor</surname><given-names>B</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name><name><surname>Dijkmans</surname><given-names>B</given-names></name><name><surname>Olivieri</surname><given-names>I</given-names></name><name><surname>Pasero</surname><given-names>G</given-names></name><etal/></person-group><article-title>The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy</article-title><source>Arthritis Rheum</source><year>1991</year><volume>34</volume><issue>10</issue><fpage>1218</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/art.1780341003</pub-id><?supplied-pmid 1930310?><pub-id pub-id-type="pmid">1930310</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Landewe</surname><given-names>R</given-names></name><name><surname>Listing</surname><given-names>J</given-names></name><name><surname>Akkoc</surname><given-names>N</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Chou</surname><given-names>CT</given-names></name><name><surname>Collantes-Estevez</surname><given-names>E</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><etal/></person-group><article-title>The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><issue>6</issue><fpage>777</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.108233</pub-id><?supplied-pmid 19297344?><pub-id pub-id-type="pmid">19297344</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poddubnyy</surname><given-names>D</given-names></name><name><surname>van Tubergen</surname><given-names>A</given-names></name><name><surname>Landewe</surname><given-names>R</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name></person-group><article-title>Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>8</issue><fpage>1483</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-207151</pub-id><?supplied-pmid 25990288?><pub-id pub-id-type="pmid">25990288</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>R</given-names></name><name><surname>de Hooge</surname><given-names>M</given-names></name><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>van Gaalen</surname><given-names>F</given-names></name><name><surname>Reijnierse</surname><given-names>M</given-names></name><name><surname>Landewe</surname><given-names>R</given-names></name><name><surname>Huizinga</surname><given-names>T</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name></person-group><article-title>ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><issue>10</issue><fpage>1646</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201884</pub-id><?supplied-pmid 23139266?><pub-id pub-id-type="pmid">23139266</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reveille</surname><given-names>JD</given-names></name></person-group><article-title>Genetics of spondyloarthritis&#8212;beyond the MHC</article-title><source>Nat Rev Rheumatol</source><year>2012</year><volume>8</volume><issue>5</issue><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2012.41</pub-id><?supplied-pmid 22487796?><pub-id pub-id-type="pmid">22487796</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>K</given-names></name><name><surname>Ahvonen</surname><given-names>P</given-names></name><name><surname>Lassus</surname><given-names>A</given-names></name><name><surname>Sievers</surname><given-names>K</given-names></name><name><surname>Tilikainen</surname><given-names>A</given-names></name></person-group><article-title>HL-A antigen 27 and reactive arthritis</article-title><source>Lancet</source><year>1973</year><volume>2</volume><issue>7821</issue><fpage>157</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(73)93109-7</pub-id><?supplied-pmid 4124084?><pub-id pub-id-type="pmid">4124084</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Amjadi</surname><given-names>S</given-names></name><name><surname>Maconochie</surname><given-names>Z</given-names></name><name><surname>Abu El-Asrar</surname><given-names>A</given-names></name><name><surname>McCluskey</surname><given-names>P</given-names></name></person-group><article-title>What is new HLA-B27 acute anterior uveitis?</article-title><source>Ocul Immunol Inflamm</source><year>2011</year><volume>19</volume><issue>2</issue><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.3109/09273948.2010.542269</pub-id><?supplied-pmid 21428757?><pub-id pub-id-type="pmid">21428757</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Porta</surname><given-names>J</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Schurman</surname><given-names>DJ</given-names></name></person-group><article-title>Clinical history as a screening test for ankylosing spondylitis</article-title><source>JAMA</source><year>1977</year><volume>237</volume><issue>24</issue><fpage>2613</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/jama.1977.03270510035017</pub-id><?supplied-pmid 140252?><pub-id pub-id-type="pmid">140252</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>Metter</surname><given-names>A</given-names></name><name><surname>Listing</surname><given-names>J</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><issue>2</issue><fpage>569</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/art.21619</pub-id><?supplied-pmid 16447233?><pub-id pub-id-type="pmid">16447233</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>R</given-names></name><name><surname>de Hooge</surname><given-names>M</given-names></name><name><surname>van Gaalen</surname><given-names>F</given-names></name><name><surname>Reijnierse</surname><given-names>M</given-names></name><name><surname>Huizinga</surname><given-names>T</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name></person-group><article-title>Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort</article-title><source>Rheumatology (Oxford)</source><year>2013</year><volume>52</volume><issue>8</issue><fpage>1492</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ket164</pub-id><pub-id pub-id-type="pmid">23650623</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>d&#8217;Agostino</surname><given-names>MA</given-names></name><name><surname>Benessiano</surname><given-names>J</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Breban</surname><given-names>M</given-names></name><name><surname>Claudepierre</surname><given-names>P</given-names></name><name><surname>Combe</surname><given-names>B</given-names></name><name><surname>Dargent-Molina</surname><given-names>P</given-names></name><name><surname>Daures</surname><given-names>JP</given-names></name><name><surname>Fautrel</surname><given-names>B</given-names></name><etal/></person-group><article-title>The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients</article-title><source>Joint Bone Spine</source><year>2011</year><volume>78</volume><issue>6</issue><fpage>598</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2011.01.013</pub-id><?supplied-pmid 21458351?><pub-id pub-id-type="pmid">21458351</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leirisalo-Repo</surname><given-names>M</given-names></name><name><surname>Hannu</surname><given-names>T</given-names></name><name><surname>Mattila</surname><given-names>L</given-names></name></person-group><article-title>Microbial factors in spondyloarthropathies: insights from population studies</article-title><source>Curr Opin Rheumatol</source><year>2003</year><volume>15</volume><issue>4</issue><fpage>408</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/00002281-200307000-00006</pub-id><?supplied-pmid 12819467?><pub-id pub-id-type="pmid">12819467</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudwaleit</surname><given-names>M</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name></person-group><article-title>How to diagnose axial spondyloarthritis early</article-title><source>Ann Rheum Dis</source><year>2004</year><volume>63</volume><issue>5</issue><fpage>535</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1136/ard.2003.011247</pub-id><?supplied-pmid 15082484?><pub-id pub-id-type="pmid">15082484</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>K</given-names></name><name><surname>Kruger</surname><given-names>K</given-names></name><name><surname>Mossner</surname><given-names>R</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis</article-title><source>Br J Dermatol</source><year>2009</year><volume>160</volume><issue>5</issue><fpage>1040</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.09023.x</pub-id><?supplied-pmid 19210498?><pub-id pub-id-type="pmid">19210498</pub-id></element-citation></ref></ref-list></back></article>